Lazard Asset Management
GRTS

Lazard Asset Management’s Gritstone bio, Inc. Common Stock GRTS Stock Holding History

Lazard Asset Management’s Portfolio GRTS Stock Details GRTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-27,461
Closed -$70K – 2467
2024
Q1 		$70K Buy
+27,461
New +$67.1K ﹤0.01% 1647
2023
Q4 		– Sell
-5,900
Closed -$9K – 2522
2023
Q3 		$9K Buy
5,900
+269
+5% +$478 ﹤0.01% 2152
2023
Q2 		$10K Buy
5,631
+149
+3% +$349 ﹤0.01% 2185
2023
Q1 		$14K Buy
5,482
+1,142
+26% +$3.26K ﹤0.01% 2105
2022
Q4 		$14K Buy
+4,340
New +$12.4K ﹤0.01% 2174
2022
Q1 		– Sell
-1,245
Closed -$16K – 2582
2021
Q4 		$16K Sell
1,245
-5,676
-82% -$62.9K ﹤0.01% 2086
2021
Q3 		$74K Sell
6,921
-577
-8% -$5.25K ﹤0.01% 1510
2021
Q2 		$68K Buy
+7,498
New +$69.3K ﹤0.01% 1475
2020
Q4 		– Sell
-200
Closed – – 2019
2020
Q3 		$0 Hold
200
– – ﹤0.01% 1764
2020
Q2 		$1K Buy
+200
New +$1.35K ﹤0.01% 1600

Other funds holding GRTS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lazard Asset Management's GRTS Position: Q2 2024 in Review

Lazard Asset Management sold out of Gritstone bio, Inc. Common Stock (GRTS) in Q2 2024, closing a stake of 27,461 shares — an estimated $70K sold.

Lazard Asset Management first reported a position in GRTS in Q2 2020 and held it in 10 quarters. The position peaked at $74K in Q3 2021. 79 funds tracked by Wall St. Rank hold GRTS as of Q2 2024.

  • Lazard Asset Management reported no remaining Gritstone bio, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Lazard Asset Management sold 27,461 Gritstone bio, Inc. Common Stock shares in Q2 2024, an estimated $70K.
  • Lazard Asset Management first reported a position in Gritstone bio, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
  • Lazard Asset Management's Gritstone bio, Inc. Common Stock position peaked at $74K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Gritstone bio, Inc. Common Stock as of Q2 2024.

Based on Lazard Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.